Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Chow BSM, Kocan M, Shen M, Wang Y, Han L, Chew JY, Wang C, Bosnyak S, Mirabito-Colafella KM, Barsha G, Wigg B, Johnstone EKM, Hossain MA, Pfleger KDG, Denton KM, Widdop RE, Summers RJ, Bathgate RAD, Hewitson TD, Samuel CS.

J Am Soc Nephrol. 2019 Sep 11. pii: ASN.2019060597. doi: 10.1681/ASN.2019060597. [Epub ahead of print]

PMID:
31511361
2.

Disease-associated missense variants in ZBTB18 disrupt DNA binding and impair the development of neurons within the embryonic cerebral cortex.

Hemming IA, Clément O, Gladwyn-Ng IE, Cullen HD, Ng HL, See HB, Ngo L, Ulgiati D, Pfleger KDG, Agostino M, Heng JI.

Hum Mutat. 2019 May 21. doi: 10.1002/humu.23803. [Epub ahead of print]

PMID:
31112317
3.

NanoBRET: The Bright Future of Proximity-Based Assays.

Dale NC, Johnstone EKM, White CW, Pfleger KDG.

Front Bioeng Biotechnol. 2019 Mar 26;7:56. doi: 10.3389/fbioe.2019.00056. eCollection 2019. Review.

4.

Complex Formation between VEGFR2 and the β2-Adrenoceptor.

Kilpatrick LE, Alcobia DC, White CW, Peach CJ, Glenn JR, Zimmerman K, Kondrashov A, Pfleger KDG, Ohana RF, Robers MB, Wood KV, Sloan EK, Woolard J, Hill SJ.

Cell Chem Biol. 2019 Jun 20;26(6):830-841.e9. doi: 10.1016/j.chembiol.2019.02.014. Epub 2019 Apr 4.

5.

Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis.

Pickering RJ, Tikellis C, Rosado CJ, Tsorotes D, Dimitropoulos A, Smith M, Huet O, Seeber RM, Abhayawardana R, Johnstone EK, Golledge J, Wang Y, Jandeleit-Dahm KA, Cooper ME, Pfleger KD, Thomas MC.

J Clin Invest. 2019 Jan 2;129(1):406-421. doi: 10.1172/JCI99987. Epub 2018 Dec 10.

6.

NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing.

White CW, Johnstone EKM, See HB, Pfleger KDG.

Cell Signal. 2019 Feb;54:27-34. doi: 10.1016/j.cellsig.2018.11.018. Epub 2018 Nov 22.

PMID:
30471466
7.

BRET-based assay to monitor EGFR transactivation by the AT1R reveals Gq/11 protein-independent activation and AT1R-EGFR complexes.

O'Brien SL, Johnstone EKM, Devost D, Conroy J, Reichelt ME, Purdue BW, Ayoub MA, Kawai T, Inoue A, Eguchi S, Hébert TE, Pfleger KDG, Thomas WG.

Biochem Pharmacol. 2018 Dec;158:232-242. doi: 10.1016/j.bcp.2018.10.017. Epub 2018 Oct 19.

PMID:
30347205
8.

Investigation of interactions between TLR2, MyD88 and TIRAP by bioluminescence resonance energy transfer is hampered by artefacts of protein overexpression.

Sampaio NG, Kocan M, Schofield L, Pfleger KDG, Eriksson EM.

PLoS One. 2018 Aug 23;13(8):e0202408. doi: 10.1371/journal.pone.0202408. eCollection 2018.

9.

Using nanoBRET and CRISPR/Cas9 to monitor proximity to a genome-edited protein in real-time.

White CW, Vanyai HK, See HB, Johnstone EKM, Pfleger KDG.

Sci Rep. 2017 Jun 9;7(1):3187. doi: 10.1038/s41598-017-03486-2.

10.

Key determinants of selective binding and activation by the monocyte chemoattractant proteins at the chemokine receptor CCR2.

Huma ZE, Sanchez J, Lim HD, Bridgford JL, Huang C, Parker BJ, Pazhamalil JG, Porebski BT, Pfleger KDG, Lane JR, Canals M, Stone MJ.

Sci Signal. 2017 May 23;10(480). pii: eaai8529. doi: 10.1126/scisignal.aai8529.

PMID:
28536301
11.

Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking.

Tiulpakov A, White CW, Abhayawardana RS, See HB, Chan AS, Seeber RM, Heng JI, Dedov I, Pavlos NJ, Pfleger KD.

Mol Endocrinol. 2016 Aug;30(8):889-904. doi: 10.1210/me.2016-1002. Epub 2016 Jun 29.

12.

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

Griffiths K, Dolezal O, Cao B, Nilsson SK, See HB, Pfleger KD, Roche M, Gorry PR, Pow A, Viduka K, Lim K, Lu BG, Chang DH, Murray-Rust T, Kvansakul M, Perugini MA, Dogovski C, Doerflinger M, Zhang Y, Parisi K, Casey JL, Nuttall SD, Foley M.

J Biol Chem. 2016 Jun 10;291(24):12641-57. doi: 10.1074/jbc.M116.721050. Epub 2016 Apr 1.

13.

G Protein-Coupled Receptor Heteromers.

Gomes I, Ayoub MA, Fujita W, Jaeger WC, Pfleger KD, Devi LA.

Annu Rev Pharmacol Toxicol. 2016;56:403-25. doi: 10.1146/annurev-pharmtox-011613-135952. Epub 2015 Oct 22. Review.

14.

Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding.

Stoddart LA, White CW, Nguyen K, Hill SJ, Pfleger KD.

Br J Pharmacol. 2016 Oct;173(20):3028-37. doi: 10.1111/bph.13316. Epub 2015 Nov 5. Review.

15.

Bioluminescence Resonance Energy Transfer Approaches to Discover Bias in GPCR Signaling.

Johnstone EK, Pfleger KD.

Methods Mol Biol. 2015;1335:191-204. doi: 10.1007/978-1-4939-2914-6_13.

PMID:
26260602
16.

Application of BRET to monitor ligand binding to GPCRs.

Stoddart LA, Johnstone EKM, Wheal AJ, Goulding J, Robers MB, Machleidt T, Wood KV, Hill SJ, Pfleger KDG.

Nat Methods. 2015 Jul;12(7):661-663. doi: 10.1038/nmeth.3398. Epub 2015 Jun 1.

17.

Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease.

Ayoub MA, Zhang Y, Kelly RS, See HB, Johnstone EK, McCall EA, Williams JH, Kelly DJ, Pfleger KD.

PLoS One. 2015 Mar 25;10(3):e0119803. doi: 10.1371/journal.pone.0119803. eCollection 2015.

18.

Homogeneous time-resolved fluorescence-based assay to monitor extracellular signal-regulated kinase signaling in a high-throughput format.

Ayoub MA, Trebaux J, Vallaghe J, Charrier-Savournin F, Al-Hosaini K, Gonzalez Moya A, Pin JP, Pfleger KD, Trinquet E.

Front Endocrinol (Lausanne). 2014 Jun 23;5:94. doi: 10.3389/fendo.2014.00094. eCollection 2014.

19.

Biophysical Detection of Diversity and Bias in GPCR Function.

Jaeger WC, Armstrong SP, Hill SJ, Pfleger KD.

Front Endocrinol (Lausanne). 2014 Mar 5;5:26. doi: 10.3389/fendo.2014.00026. eCollection 2014. Review.

20.

Molecular determinants of orexin receptor-arrestin-ubiquitin complex formation.

Jaeger WC, Seeber RM, Eidne KA, Pfleger KD.

Br J Pharmacol. 2014 Jan;171(2):364-74. doi: 10.1111/bph.12481.

21.

Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).

Armstrong SP, Seeber RM, Ayoub MA, Feldman BJ, Pfleger KD.

PLoS One. 2013 Jun 6;8(6):e65885. doi: 10.1371/journal.pone.0065885. Print 2013.

22.

Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.

Ayoub MA, See HB, Seeber RM, Armstrong SP, Pfleger KD.

PLoS One. 2013 May 20;8(5):e64672. doi: 10.1371/journal.pone.0064672. Print 2013.

23.

Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes.

Watts AO, van Lipzig MM, Jaeger WC, Seeber RM, van Zwam M, Vinet J, van der Lee MM, Siderius M, Zaman GJ, Boddeke HW, Smit MJ, Pfleger KD, Leurs R, Vischer HF.

Br J Pharmacol. 2013 Apr;168(7):1662-74. doi: 10.1111/bph.12064.

24.

Receptor-Heteromer Investigation Technology and its application using BRET.

Johnstone EK, Pfleger KD.

Front Endocrinol (Lausanne). 2012 Aug 22;3:101. doi: 10.3389/fendo.2012.00101. eCollection 2012.

25.

Effect of enhanced Renilla luciferase and fluorescent protein variants on the Förster distance of Bioluminescence resonance energy transfer (BRET).

Dacres H, Michie M, Wang J, Pfleger KD, Trowell SC.

Biochem Biophys Res Commun. 2012 Aug 31;425(3):625-9. doi: 10.1016/j.bbrc.2012.07.133. Epub 2012 Aug 1.

26.

mGlu5 Receptor Functional Interactions and Addiction.

Brown RM, Mustafa S, Ayoub MA, Dodd PR, Pfleger KD, Lawrence AJ.

Front Pharmacol. 2012 May 7;3:84. doi: 10.3389/fphar.2012.00084. eCollection 2012.

27.

Deleterious GRM1 mutations in schizophrenia.

Ayoub MA, Angelicheva D, Vile D, Chandler D, Morar B, Cavanaugh JA, Visscher PM, Jablensky A, Pfleger KD, Kalaydjieva L.

PLoS One. 2012;7(3):e32849. doi: 10.1371/journal.pone.0032849. Epub 2012 Mar 20.

28.

Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer.

Mustafa S, See HB, Seeber RM, Armstrong SP, White CW, Ventura S, Ayoub MA, Pfleger KD.

J Biol Chem. 2012 Apr 13;287(16):12952-65. doi: 10.1074/jbc.M111.322834. Epub 2012 Feb 27.

29.

G protein-coupled receptor heteromer identification technology: identification and profiling of GPCR heteromers.

Mustafa S, Pfleger KD.

J Lab Autom. 2011 Aug;16(4):285-91. doi: 10.1016/j.jala.2011.03.002. Epub 2011 May 31.

30.

Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles.

Porrello ER, Pfleger KD, Seeber RM, Qian H, Oro C, Abogadie F, Delbridge LM, Thomas WG.

Cell Signal. 2011 Nov;23(11):1767-76. doi: 10.1016/j.cellsig.2011.06.011. Epub 2011 Jun 25.

PMID:
21740964
31.

Study of GPCR-protein interactions by BRET.

Kocan M, Pfleger KD.

Methods Mol Biol. 2011;746:357-71. doi: 10.1007/978-1-61779-126-0_20.

PMID:
21607868
32.

Temporal profiling of orexin receptor-arrestin-ubiquitin complexes reveals differences between receptor subtypes.

Dalrymple MB, Jaeger WC, Eidne KA, Pfleger KD.

J Biol Chem. 2011 May 13;286(19):16726-33. doi: 10.1074/jbc.M111.223537. Epub 2011 Mar 4.

33.

Application of G protein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers.

See HB, Seeber RM, Kocan M, Eidne KA, Pfleger KD.

Assay Drug Dev Technol. 2011 Feb;9(1):21-30. doi: 10.1089/adt.2010.0336. Epub 2010 Dec 6.

34.

Differential association modes of the thrombin receptor PAR1 with Galphai1, Galpha12, and beta-arrestin 1.

Ayoub MA, Trinquet E, Pfleger KD, Pin JP.

FASEB J. 2010 Sep;24(9):3522-35. doi: 10.1096/fj.10-154997. Epub 2010 Apr 21.

PMID:
20410441
35.

Enhanced BRET Technology for the Monitoring of Agonist-Induced and Agonist-Independent Interactions between GPCRs and β-Arrestins.

Kocan M, Dalrymple MB, Seeber RM, Feldman BJ, Pfleger KD.

Front Endocrinol (Lausanne). 2011 Jan 14;1:12. doi: 10.3389/fendo.2010.00012. eCollection 2010.

36.

Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization.

Ayoub MA, Pfleger KD.

Curr Opin Pharmacol. 2010 Feb;10(1):44-52. doi: 10.1016/j.coph.2009.09.012. Epub 2009 Nov 10. Review.

PMID:
19897419
37.

Analysis of protein-protein interactions using bioluminescence resonance energy transfer.

Pfleger KD.

Methods Mol Biol. 2009;574:173-83. doi: 10.1007/978-1-60327-321-3_14.

PMID:
19685308
38.

Detection of GPCR/beta-arrestin interactions in live cells using bioluminescence resonance energy transfer technology.

Kocan M, Pfleger KD.

Methods Mol Biol. 2009;552:305-17. doi: 10.1007/978-1-60327-317-6_22.

PMID:
19513659
39.

Building a new conceptual framework for receptor heteromers.

Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, Mackie K, Milligan G, Pfleger KD, Pin JP, Volkow ND, Waldhoer M, Woods AS, Franco R.

Nat Chem Biol. 2009 Mar;5(3):131-4. doi: 10.1038/nchembio0309-131.

40.

Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis.

Kocan M, See HB, Sampaio NG, Eidne KA, Feldman BJ, Pfleger KD.

Mol Endocrinol. 2009 Apr;23(4):559-71. doi: 10.1210/me.2008-0321. Epub 2009 Jan 29.

41.

Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells.

Kocan M, See HB, Seeber RM, Eidne KA, Pfleger KD.

J Biomol Screen. 2008 Oct;13(9):888-98. doi: 10.1177/1087057108324032. Epub 2008 Sep 23.

PMID:
18812574
42.

G protein-coupled receptor dimers: functional consequences, disease states and drug targets.

Dalrymple MB, Pfleger KD, Eidne KA.

Pharmacol Ther. 2008 Jun;118(3):359-71. doi: 10.1016/j.pharmthera.2008.03.004. Epub 2008 Apr 8. Review.

PMID:
18486226
43.

G protein coupled receptors as drug targets: the role of beta-arrestins.

Dromey JR, Pfleger KD.

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):51-61. Review.

PMID:
18393923
44.
45.

Monitoring interactions between G-protein-coupled receptors and beta-arrestins.

Pfleger KD, Dalrymple MB, Dromey JR, Eidne KA.

Biochem Soc Trans. 2007 Aug;35(Pt 4):764-6. Review.

PMID:
17635143
46.
47.

Extended bioluminescence resonance energy transfer (eBRET) for monitoring prolonged protein-protein interactions in live cells.

Pfleger KD, Dromey JR, Dalrymple MB, Lim EM, Thomas WG, Eidne KA.

Cell Signal. 2006 Oct;18(10):1664-70. Epub 2006 Feb 21.

PMID:
16492395
48.
49.
50.

Receptors for hypothalamic releasing hormones TRH and GnRH: oligomerization and interactions with intracellular proteins.

Pfleger KD, Kroeger KM, Eidne KA.

Semin Cell Dev Biol. 2004 Jun;15(3):269-80. Review.

PMID:
15125890

Supplemental Content

Loading ...
Support Center